KJHP
VVOS icon

K.J. Harrison & Partners’s Vivos Therapeutics VVOS Stock Holding History

K.J. Harrison & Partners’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,817
Closed -$302K – 391
2021
Q1 		$302K Sell
1,817
-1,836
-50% -$328K 0.05% 227
2020
Q4 		$540K Buy
+3,653
New +$667K 0.09% 197

Other funds holding VVOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
AIA
Avalon Investment & Advisory Houston, Texas $3.65B AUM 0.47% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
MAG
Millrace Asset Group Berwyn, Pennsylvania $98.4M AUM 63.71% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return

K.J. Harrison & Partners's VVOS Position: Q2 2021 in Review

K.J. Harrison & Partners sold out of Vivos Therapeutics (VVOS) in Q2 2021, closing a stake of 1,817 shares — an estimated $302K sold.

K.J. Harrison & Partners first reported a position in VVOS in Q4 2020 and held it in 2 quarters. The position peaked at $540K in Q4 2020. 29 funds tracked by Wall St. Rank hold VVOS as of Q2 2021.

  • K.J. Harrison & Partners reported no remaining Vivos Therapeutics position as of Q2 2021 after selling out during the quarter.
  • K.J. Harrison & Partners sold 1,817 Vivos Therapeutics shares in Q2 2021, an estimated $302K.
  • K.J. Harrison & Partners first reported a position in Vivos Therapeutics in Q4 2020 and held it in 2 quarters.
  • K.J. Harrison & Partners's Vivos Therapeutics position peaked at $540K in Q4 2020.
  • 29 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2021.

Based on K.J. Harrison & Partners's 13F filing for Q2 2021, filed 4 Aug 2021.